Previous studies combining proteomics with animal models of SMA have mainly utilized the technology to uncover molecular pathways disrupted downstream of SMN [7,30,35,36], but the current study demonstrates that similar approaches can be used to identify potential protein biomarkers for future use in the human clinical context. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.